MaxCyte, Inc.

MXCT

$1.26

-0.79%

N/A-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists ...

Key Metrics of MXCT

Snapshot

Latest / TTM · 6 periods

Market Cap

$134.97M

ROCE

-19.8%

EV / EBITDA

-4.23x

+4.2% YoY

FCF Yield

-17.6%

+4.3% YoY

Cash Conversion Cycle

392.7d

Current Ratio

12.26

Quick take

TTM —

Positive CCC

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$923.41M	$555.30M	$485.36M	$436.17M	$164.96M	$134.97M
Enterprise ValueCompany value including debt and cash adjustments.	$881.31M	$560.33M	$457.60M	$426.32M	$162.84M	$137.18M
EV / SalesHow many dollars investors pay per dollar of sales.	26.00x	12.66x	11.08x	11.04x	4.93x	4.42x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-53.05x	-27.01x	-13.56x	-11.76x	-4.12x	-4.23x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	2.53	-0.24	0.82	0.27	0.05	-0.07

Returns + ROCE gauge

ROCE latest

-19.8%

Prev year -24.1%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-7.3%	-9.3%	-16.3%	-19.9%	-26.0%	-21.0%
ROAProfit generated from total assets.	-6.7%	-8.2%	-14.1%	-17.1%	-22.0%	-19.3%
ROICReturn generated on invested operating capital.	-6.7%	-8.7%	-18.3%	-22.0%	-33.5%	-25.9%
ROCEOperating return on long-term capital used.	-6.8%	-10.1%	-19.3%	-22.9%	-24.1%	-19.8%
Earnings YieldEarnings as a percentage of market value.	-2.1%	-4.2%	-7.8%	-9.4%	-27.1%	-26.5%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-13.47M	$-33.13M	$-25.39M	$-29.26M	$-36.18M	$-23.79M
FCFECash flow available to equity holders after debt flows.	$-19.50M	$-33.26M	$-25.39M	$-29.26M	$-36.18M	$-23.79M
FCF YieldFree cash flow divided by market capitalization.	-1.6%	-6.0%	-5.2%	-6.7%	-21.9%	-17.6%
Income QualityHow well accounting earnings are backed by cash flow.	0.56	0.63	0.57	0.67	0.77	0.64
Capex / OCFShare of operating cash flow spent on capital expenditures.	-35.9%	-125.0%	-17.1%	-6.0%	-5.1%	-3.5%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	74.1d	92.2d	51.1d	44.2d	38.7d	46.1d
DIOAverage days inventory stays before being sold.	520.8d	614.4d	941.3d	458.3d	442.7d	445.7d
DPOAverage days the company takes to pay suppliers.	182.2d	20.9d	57.2d	69.8d	82.2d	99.1d
Operating CycleTime from buying inventory to collecting receivables.	594.9d	706.5d	992.4d	502.5d	481.4d	491.8d
Cash Conversion CycleNet days cash is tied in operations.	412.7d	685.6d	935.2d	432.7d	399.3d	392.7d

Snapshot

Latest / TTM: —

Market Cap

$134.97M

ROE

-21.0%

FCF Yield

-17.6%

Current Ratio

12.26

Upstream

Unnamed Electronic Components Suppliers (Single-Source)Unnamed Third-Party Cleanroom Assembly ManufacturersUnnamed Plastics & Consumables Component SuppliersSynthego (Collaboration Partner)Ori Biotech

Downstream

Vertex PharmaceuticalsNASDAQ:VRTX CRISPR TherapeuticsNASDAQ:CRSP Sana BiotechnologyNASDAQ:SANA Beam TherapeuticsNASDAQ:BEAM Legend BiotechNASDAQ:LEGN Prime MedicineNASDAQ:PRME Nkarta, Inc.NASDAQ:NKTX TG TherapeuticsNASDAQ:TGTX Adicet BioNASDAQ:ACET LG ChemKRX:051910Kamau TherapeuticsWugen, Inc.Anocca ABMoonlight BioIntima BioscienceCuramysBe BiopharmaLion TCRKSQ TherapeuticsPHC Corporation (PHCbi) – Biomedical Division of PHC HoldingsTSE:6526Porton Advanced (subsidiary of Porton Pharma Solutions)SZSE:300363CTMC (Cell Therapy Manufacturing Center – JV: MD Anderson / Resilience)

Proxies

Vertex PharmaceuticalsNASDAQ:VRTX CRISPR TherapeuticsNASDAQ:CRSPLonza GroupSWX:LONNThermo Fisher ScientificNYSE:TMO Bio-Rad LaboratoriesNYSE:BIO

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

MaxCyte, Inc.

Key Metrics of MXCT

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of MXCT

Upstream

Downstream

Proxies

Key Metrics of MXCT

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of MXCT

Upstream

Downstream

Proxies